Submit Deal

Announced

15 Feb 2022

Gilead Sciences to invest $35m in HOOKIPA Pharma.

Synopsis

Gilead Sciences, an American biopharmaceutical company, to invest $35m in HOOKIPA Pharma, a clinical-stage biopharmaceutical company. "Gilead is helping to advance our novel arenaviral platform technology, which has the potential to complement Gilead’s overall research strategies for cures of HIV and HBV," Joern Aldag, HOOKIPA CEO.

Principals

target

Hookipa Pharma

bidder

Gilead Sciences

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (3)

matt beck

Executive Director Investor Relations at HOOKIPA PHARMA

Manager

target

Deal

£ 26 M

Total Value

joern aldag

CEO at HOOKIPA PHARMA

Manager

target

Deal

£ 26 M

Total Value

reinhard kandera

CFO at HOOKIPA PHARMA

Manager

target

Deal

£ 26 M

Total Value

Bidder Team (8)

daniel o'day

Chairman and CEO at GILEAD SCIENCES

Manager

bidder

Deals

£ 28.54 B

Total Value

spencer leroux

Law Clerk at Hogan Lovells

Lawyer

bidder

Deals

£ 14.21 B

Total Value

kevin k. greenslade

Partner at Hogan Lovells

Lawyer

bidder

Deals

£ 1.73 B

Total Value

emma dowell

Senior Associate at Hogan Lovells

Lawyer

bidder

Deals

£ 4.22 B

Total Value

cullen taylor

Partner at Hogan Lovells

Lawyer

bidder

Deals

£ 1.70 B

Total Value

henry watsky

Associate at Hogan Lovells

Lawyer

bidder

Deals

£ 531 M

Total Value

andrew dickinson

CFO at GILEAD SCIENCES

Manager

bidder

Deals

£ 31.03 B

Total Value

hamza rashid

Associate at Hogan Lovells

Lawyer

bidder

Deals

£ 961 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy